Published in Blood Weekly, May 17th, 2007
VTE is the formation of a blood clot that can travel from a leg vein to the lung, with potentially fatal results. FRAGMIN is the first low-molecular- weight heparin (LMWH) approved in the U.S. for the extended treatment of recurrent VTE in patients with cancer.
"Cancer treatments and the disease itself put this patient population at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.